Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2014; 20(17): 5098-5103
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer
Jing-Ping Yu, Su-Ping Sun, Zhi-Qiang Sun, Xin-Chu Ni, Jian Wang, Yi Li, Li-Jun Hu, Dong-Qing Li, Department of Radiation Oncology, Changzhou Second People’s Hospital, Affiliated to Nanjing Medical University, Changzhou 213003, Jiangsu Province, China
Author contributions: Yu JP and Sun ZQ wrote the manuscript; Yu JP and Sun SP revised the manuscript; Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, Hu LJ and Li DQ contributed to the provision of study materials and patients.
Supported by Leading Scientific Research Project of the Health Department of Jiangsu Province, China, No. Z201220; Major Project of the Health Department of Changzhou, China, No. ZD201105; and Changzhou Sci-Tech Support Project for Social Development, No. CE20125021
Correspondence to: Su-Ping Sun, PhD, Department of Radiation Oncology, Changzhou Second People’s Hospital, Affiliated to Nanjing Medical University, Labor Lane, Changzhou 213003, Jiangsu Province, China. ssp56@126.com
Telephone: + 86-519-88118723 Fax: + 86-519-88115560
Received: November 25, 2013
Revised: February 25, 2014
Accepted: March 4, 2014
Published online: May 7, 2014
Revised: February 25, 2014
Accepted: March 4, 2014
Published online: May 7, 2014
Core Tip
Core tip: Vascular endothelial growth factor (VEGF)-based individualized radiotherapy for esophageal cancer (EC) was achieved in this clinical study. EC patients undergoing radiation treatment may receive different protocols: thalidomide combined with radiation or radiation alone, according to their VEGF level. This study was designed to set appropriate radiotherapy regimens for different patients, improve sensitivity, and decrease resistance in radiation oncology.